Cellaria introduces new models to study pancreatic cancer

By The Science Advisory Board staff writers

October 15, 2020 -- Cellaria has launched three new cell lines for pancreatic cancer that it hopes will improve patient care by improving the value of in vitro methods of developing therapies.

The new cell models are called Stew, Chocolate, and Basket, and are linked to specific patient tumor samples and feature different constellations of patient factors such as gender, ethnicity, age, treatment history, and diagnosis. This diversity allows researchers to match their studies with particular patient cohorts, the company said.

If you like this content, please share it with a colleague!

Related Reading

Lantern Pharma, Fox Chase to develop pancreatic cancer drug
Lantern Pharma will leverage its response algorithm for drug repositioning and rescue (RADR) artificial intelligence platform in collaboration with Fox...

PanCan, GeneCentric partner on precision medicine for pancreatic cancer
The Pancreatic Cancer Action Network (PanCan) and GeneCentric Therapeutics have partnered to conduct research on RNA-based molecular technologies to predict...

Innovations in synthetic chemistry help identify new cancer therapies
The pathway to discovering and developing cancer therapies is not always linear, but well-designed models incorporating smart chemical innovations can...

CARsgen receives IND clearance for cell therapy
CARsgen Therapeutics has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration for a cell therapy drug for advanced...

3D magnetic cell culture transforms cancer therapy screening
Traditional high-throughput drug screening in oncology routinely relies on 2D cell models, which inadequately recapitulate the physiologic context of...